JP Morgan Chase
CERE

JP Morgan Chase’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

JP Morgan Chase’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-697,510
Closed -$28.5M – 7812
2024
Q2 		$28.5M Buy
697,510
+257,344
+58% +$10.7M ﹤0.01% 1592
2024
Q1 		$18.6M Buy
440,166
+283,358
+181% +$11.9M ﹤0.01% 1939
2023
Q4 		$6.65M Buy
156,808
+59,523
+61% +$1.71M ﹤0.01% 2835
2023
Q3 		$2.12M Sell
97,285
-64,066
-40% -$1.6M ﹤0.01% 3498
2023
Q2 		$5.13M Sell
161,351
-1,343
-0.8% -$41.2K ﹤0.01% 2839
2023
Q1 		$3.97M Buy
162,694
+31,722
+24% +$931K ﹤0.01% 3006
2022
Q4 		$4.13M Buy
130,972
+498
+0.4% +$14.1K ﹤0.01% 2988
2022
Q3 		$3.69M Buy
130,474
+71,361
+121% +$2.13M ﹤0.01% 2993
2022
Q2 		$1.56M Buy
59,113
+10,907
+23% +$310K ﹤0.01% 3739
2022
Q1 		$1.69M Buy
48,206
+5,467
+13% +$160K ﹤0.01% 3889
2021
Q4 		$1.39M Buy
42,739
+13,345
+45% +$471K ﹤0.01% 4144
2021
Q3 		$868K Buy
29,394
+5,595
+24% +$157K ﹤0.01% 4415
2021
Q2 		$610K Buy
23,799
+21,164
+803% +$303K ﹤0.01% 4576
2021
Q1 		$36K Buy
+2,635
New +$38.6K ﹤0.01% 5610

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

JP Morgan Chase's CERE Position: Q3 2024 in Review

JP Morgan Chase sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 697,510 shares — an estimated $28.5M sold.

JP Morgan Chase first reported a position in CERE in Q1 2021 and held it in 14 quarters. The position peaked at $28.5M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • JP Morgan Chase reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • JP Morgan Chase sold 697,510 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $28.5M.
  • JP Morgan Chase first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 14 quarters.
  • JP Morgan Chase's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $28.5M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.